These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16487172)

  • 1. Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia.
    Scholz M; Engel C; Loeffler M;
    Br J Haematol; 2006 Mar; 132(6):723-35. PubMed ID: 16487172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [High-dose biweekly CHOP chemotherapy with granulocyte colony-stimulating factor support for patients with aggressive non-Hodgkin lymphoma].
    Taguchi H; Shishido T; Niitsu N; Hiraoka A; Kageyama T; Kanamaru A; Ogawa M
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):523-9. PubMed ID: 9530358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
    Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI
    J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
    Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
    Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Alliot C
    J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
    [No Abstract]   [Full Text] [Related]  

  • 6. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
    Tsukasaki K; Utsunomiya A; Fukuda H; Shibata T; Fukushima T; Takatsuka Y; Ikeda S; Masuda M; Nagoshi H; Ueda R; Tamura K; Sano M; Momita S; Yamaguchi K; Kawano F; Hanada S; Tobinai K; Shimoyama M; Hotta T; Tomonaga M;
    J Clin Oncol; 2007 Dec; 25(34):5458-64. PubMed ID: 17968021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
    Hernàndez DE; Hernàndez AE
    Eur J Cancer Care (Engl); 2006 Dec; 15(5):493-6. PubMed ID: 17177909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
    Sugimoto T; Matano S; Nishijima H; Kakuta K; Inamura K; Okamura T; Munemoto S; Satoh S
    Gan To Kagaku Ryoho; 2007 Jan; 34(1):125-8. PubMed ID: 17220687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the chemotherapeutic agents for non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), on the male rat reproductive system and progeny outcome.
    Vaisheva F; Delbes G; Hales BF; Robaire B
    J Androl; 2007; 28(4):578-87. PubMed ID: 17409468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.
    Schirm S; Engel C; Loibl S; Loeffler M; Scholz M
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):343-358. PubMed ID: 29103159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of G-CSF during first line chemotherapy adversely affects the yield of PBSC mobilization in non-Hodgkin's lymphoma patients.
    Damiani D; Grimaz S; Sperotto A; Geromin A; Skert C; Cerno M; Rinaldi C; Fanin R
    Adv Clin Path; 2002 Jan; 6(1):11-6. PubMed ID: 17582943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.
    Bosly A; Bron D; Van Hoof A; De Bock R; Berneman Z; Ferrant A; Kaufman L; Dauwe M; Verhoef G
    Ann Hematol; 2008 Apr; 87(4):277-83. PubMed ID: 17952688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma.
    Lokich JJ
    Am J Clin Oncol; 2006 Aug; 29(4):361-3. PubMed ID: 16891862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas.
    Held G; Schubert J; Reiser M; Pfreundschuh M;
    Semin Hematol; 2006 Oct; 43(4):221-9. PubMed ID: 17027656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
    Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
    Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
    Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
    Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
    Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
    Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.